Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%
Lithium
44.13
(1.23%)
Gold
2,661.90
-0%
Copper
4.20
1.47%
Oil
69.59
2.1%
Bitcoin
95,969.62
0.12%
FTSE 100
8,361.55
0.59%
Nikkei 225
39,248.86
1.29%
Dow Jones
44,646.78
(0.27%)
Iron Ore
105.10
0.47%
USD/AUD
0.65
(0.09%)
Hang Seng
19,746.32
0.82%

PharmAust (ASX:$PAA) invited to apply for Phase 2/3 grant funding

PharmAust invited to apply for grant funding


PharmAust Limited (ASX:$PAA), a clinical-stage biotechnology company, has been invited by FightMND to submit a full grant application to help fund its Phase 2/3 Clinical Study for the treatment of Motor Neurone Disease/Amyotrophic Lateral Sclerosis (MND/ALS). The grant, offering up to AUD $1,800,000 in support, is available per successful application, with a deadline set for the 24th of March 2024. PharmAust's planned Phase 2/3 study is a multicentre, randomised, placebo-controlled, adaptive clinical study evaluating the safety and efficacy of monepantel in patients with MND/ALS over 48 weeks.

PharmAust CEO's perspective on the grant invitation


Gaining access to undiluted funds to help offset the costs of drug development is a goal of every biotechnology company. FightMND has already been influential to date in the development of monepantel for MND/ALS by fully funding our initial Phase 1 study. Based on the potential shown to date for monepantel to provide patients with MND/ALS with a treatment benefit were are excited at our prospects of securing further funding from FightMND for our adaptive Phase 2/3 study.

PharmAust's Phase 2/3 study and future outlook


PharmAust Limited (ASX:PAA) has been invited by FightMND to apply for grant funding to support its planned Phase 2/3 study, which aims to evaluate the safety and efficacy of monepantel in patients with MND/ALS over 48 weeks. The company's CEO, Dr Michael Thurn, expressed enthusiasm about the potential to secure further funding from FightMND for the adaptive Phase 2/3 study. PharmAust's focus on repurposing monepantel for human neurodegenerative diseases and treating cancer in dogs reflects its commitment to addressing critical health challenges. With the completion of a Phase 1 study in patients with MND/ALS and anticipated Phase 2 study in H1 2024, PharmAust is poised to contribute significantly to the advancement of treatments for MND/ALS and other related conditions.

0 Comments
Inline Feedbacks
View all comments
Social Media Auto Publish Powered By : XYZScripts.com

Stock Piper AI Index Coming Soon!

Join our Newsletter to gain exclusive insight and be notified once we are live.

By clicking Subscribe, you agree to our Terms & Conditions

ASX News, First And Fast.

Get all the latest market updates straight to your inbox.

By clicking Subscribe, you agree to our Terms & Conditions